PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.63%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.63%
Negative gross profit growth while MRVL is at 3.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
137.71%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
137.71%
Operating income growth above 1.5x MRVL's 15.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-11.23%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-14.29%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-14.29%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.68%
10Y revenue/share CAGR at 50-75% of MRVL's 56.20%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
30.68%
5Y revenue/share CAGR under 50% of MRVL's 109.65%. Michael Burry would suspect a significant competitive gap or product weakness.
30.68%
3Y revenue/share CAGR 1.25-1.5x MRVL's 25.49%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
709.89%
Similar net income/share CAGR to MRVL's 653.69%. Walter Schloss would see parallel tailwinds or expansions for both firms.
709.89%
5Y net income/share CAGR above 1.5x MRVL's 220.76%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
709.89%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.